Abstract
Tepotinib is a MET inhibitor approved by the European Commission for patients (pts) with advanced METex14 skipping NSCLC, with prior immunotherapy (IO) and/or platinum-based chemotherapy (CT). Here, we report the first analysis of tepotinib according to prior therapies from all pts with METex14 skipping NSCLC in VISION (data cut-off: Feb 20, 2022).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
